Lipoprotein(a) testing in lipid clinics across the UK: Results of a national survey

Area of Science:

• Cardiovascular Medicine
• Clinical Chemistry
• Public Health

Background:

• Lipoprotein(a) is a recognized independent risk factor for cardiovascular disease.
• Guidelines recommend its use in cardiovascular disease risk stratification.
• Understanding current clinical practice is crucial for improving patient care.

Purpose of the Study:

• To assess the availability and utilization of Lipoprotein(a) testing in UK lipid clinics.
• To identify current practices in Lipoprotein(a) measurement and risk assessment.
• To highlight disparities in Lipoprotein(a) testing accessibility and application.

Main Methods:

• A survey was distributed to UK lipid clinics.
• Response rate was 27% (53 out of ~200 clinics).
• Data collected on test availability, ordering frequency, indications, risk grading, cascade testing, and reporting units.

Main Results:

• 81% of responding clinics had access to Lipoprotein(a) testing.
• 52% of clinics ordered 0-250 tests annually.
• Primary indication was premature cardiovascular disease history; 60% measured it once per patient.
• Reporting units (nmol/L, mg/dL, mg/L) were inconsistent across clinics.

Conclusions:

• While Lipoprotein(a) testing is widely available, its application and frequency are limited.
• Inconsistent reporting units and varied clinical application hinder effective risk assessment.
• A national strategy is needed for universal access and standardized clinical use of Lipoprotein(a) measurements.